Predictors of Significant Fibrosis Among People Living with HIV with Metabolic Dysfunction- Associated Steatotic Liver Disease DOI Creative Commons
Thaninee Prasoppokakorn,

Varisa Limpijankit,

Siravich Seesodsai

et al.

Deleted Journal, Journal Year: 2024, Volume and Issue: 76(12), P. 797 - 809

Published: Dec. 1, 2024

Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent among people living with HIV (PLWH) due to comorbidities and factors related infection. This study aimed identify clinical predictors of significant fibrosis PLWH MASLD. Materials Methods: A retrospective cohort was conducted having CD4 counts ≥200, enrolled between April October 2023 at two tertiary hospitals. The primary outcome identifying the (F≥2) defined by TE≥8 kPa. Secondary outcomes included MASLD prevalenceand characteristics. Results: Among 96 PLWH, 52 (54.2%) had mean age 49.7±8.0 years, 63.5% were male, BMI 25.8±4.1 kg/m². Obesity, diabetes, dyslipidemia present in 17.3%, 19.2%, 46.2% participants, respectively. CAP TE 285±36 dB/m 8.7±7.8 kPa, Significantfibrosis 24 patients (46.2%). Fibrosis scoring systems (FIB-4, APRI, NFS) demonstrated good accuracy (AUROCs: 0.84, 0.85, 0.76, respectively). Multivariate analysis identified fibrosis: higher (aOR 1.24, p=0.042), 3.96, p=0.038), AST 1.19, p=0.011). AGA pathway using steps (FIB-4 TE) improved reclassification risk, reducing number individuals indeterminate 12 out first step 7 second step. Conclusion: about half experiencing fibrosis. Predictors include dyslipidemia, BMI, elevated levels. accurately predict

Language: Английский

Prevalence, characteristics and outcomes of patients with metabolic and alcohol related/associated liver disease: a systematic review and meta-analysis DOI
Maria Tampaki, Emmanuel Tsochatzis, Vasileios Lekakis

et al.

Metabolism, Journal Year: 2024, Volume and Issue: 163, P. 156101 - 156101

Published: Dec. 10, 2024

Language: Английский

Citations

1
Predictors of Significant Fibrosis Among People Living with HIV with Metabolic Dysfunction- Associated Steatotic Liver Disease DOI Creative Commons
Thaninee Prasoppokakorn,

Varisa Limpijankit,

Siravich Seesodsai

et al.

Deleted Journal, Journal Year: 2024, Volume and Issue: 76(12), P. 797 - 809

Published: Dec. 1, 2024

Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent among people living with HIV (PLWH) due to comorbidities and factors related infection. This study aimed identify clinical predictors of significant fibrosis PLWH MASLD. Materials Methods: A retrospective cohort was conducted having CD4 counts ≥200, enrolled between April October 2023 at two tertiary hospitals. The primary outcome identifying the (F≥2) defined by TE≥8 kPa. Secondary outcomes included MASLD prevalenceand characteristics. Results: Among 96 PLWH, 52 (54.2%) had mean age 49.7±8.0 years, 63.5% were male, BMI 25.8±4.1 kg/m². Obesity, diabetes, dyslipidemia present in 17.3%, 19.2%, 46.2% participants, respectively. CAP TE 285±36 dB/m 8.7±7.8 kPa, Significantfibrosis 24 patients (46.2%). Fibrosis scoring systems (FIB-4, APRI, NFS) demonstrated good accuracy (AUROCs: 0.84, 0.85, 0.76, respectively). Multivariate analysis identified fibrosis: higher (aOR 1.24, p=0.042), 3.96, p=0.038), AST 1.19, p=0.011). AGA pathway using steps (FIB-4 TE) improved reclassification risk, reducing number individuals indeterminate 12 out first step 7 second step. Conclusion: about half experiencing fibrosis. Predictors include dyslipidemia, BMI, elevated levels. accurately predict

Language: Английский

Citations

0